

# NEWS RELEASE



February 17, 2023

## **NS Pharma Announces First Patient Enrolled in Phase 2 Study to Assess Efficacy and Safety of NS-018 Compared to Best Available Therapy (BAT) in Patients With Myelofibrosis**

*NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)*

**Paramus, NJ: February 17, 2023** - NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer.

The Phase 2b study is an open-label, multicenter, randomized, controlled, 2-arm study to assess the efficacy and safety of orally administered NS-018 versus best available therapy in subjects with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (Platelet Count <50,000/ $\mu$ L).

ClinicalTrials.gov identifier: NCT04854096

<https://clinicaltrials.gov/ct2/show/NCT04854096>

### **About Myelofibrosis (MF)**

MF is caused by buildup of excessive scar tissue in the bone marrow, which impairs the body's ability to produce blood cells.<sup>1</sup> In addition to impaired blood cell production, MF often leads to enlargement of the spleen (splenomegaly) which can lead to feelings of abdominal pain and pressure.<sup>1</sup> Other common symptoms include fatigue, bone pain, fever, and weight loss.<sup>1</sup> MF can be diagnosed at any age but is most common in men and women 65 years or older.<sup>1</sup> The median survival of patients with MF is approximately six years.<sup>1</sup> Several gene mutations are associated with MF, and the most common mutation is to the Janus kinase 2 (JAK2) gene.<sup>2</sup>

### **About NS-018**

NS-018 is a highly selective and potent inhibitor of JAK2 developed by scientists from Nippon Shinyaku and was recently granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).

**About NS Pharma, Inc.**

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit <http://www.nspharma.com>. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

**U.S. Media Contact:**

[media@nspharma.com](mailto:media@nspharma.com)

**References:**

1. What is primary myelofibrosis? MPN Research Foundation.  
Accessed at: <https://www.mpnresearchfoundation.org/primary-myelofibrosis-pmf/>
2. Myelofibrosis. Mayo Clinic.  
Accessed at: <https://www.mayoclinic.org/diseases-conditions/myelofibrosis/symptoms-causes/syc-20355057>